Indication Half-life (T1/2), Metabolism Notable Side Effects Initial Dosing
Neurotransmitter(s) (CYP 450 enzyme) (link to NT or affected Considerations
Affected brain circuit) Specific lifespan
Target Symptoms considerations (age,
pregnancy,
breastfeeding)
Buprenorphine • Indications: • Metabolized by • Notable side • Initial dosing:
(Subutex) Induction of CYP450 3A4. effects: Day 1: 8 mg
treatment for • Elimination half-life of Headache, Day 2: 12-16
opioid dependence sublingual constipation, mg Days 3-7:
(Bunavail only), buprenorphine is 24-42 nausea, oral Increase in
maintenance hours. hypoesthesia, increments of 4
treatment of • Elimination half-life glossodynia, mg, maximum
opioid dependence naloxone is 2-12 hours. orthostatic 32 mg.
(sublingual), • Implant: Tmax is 12 hypotension, • Consideration
maintenance hours; time to steady implant specific: s: Use with
state is 4 weeks.
treatment of insertion site caution in the
opioid dependence pain, pruritus, elderly and
in patients who erythema. those with
have achieved and • Life- cardiac
sustained threatening side impairment. It
prolonged clinical effects: may be
stability on low- Respiratory preferable to
to-moderate doses depression, methadone in
(no more than hepatoxicity. pregnant
8mg) of a • How drug women.
transmucosal causes side Neonatal
buprenorphine- effects: Binding withdrawal
containing product at mu opioid may occur. The
(implant), receptors. drug is found in
moderate to serve breast milk and
opioid use is
disorder in recommended
NR 546 week 6 medication table
, patients who have for DC drug or
initiated treatment bottle feed.
with a Safety and
transmucosal efficacy have
buprenorphine- not been
containing established for
product, followed children and
by dose adolescents.
adjustment for a
minimum of 7
days (injection).
• Neurotransmitter
s affected: Mu
opioid receptor
partial agonist.
Binds with a
strong affinity to
the mu opioid
receptor,
preventing
exogenous opioids
from binding there
and thus
preventing the
pleasurable effects
of opioid
consumption.
• Target
symptoms: opioid
dependence.
Buprenorphine/ • Indications: • Half-life: Suboxone: • Notable side • Initial dosing:
Naloxone (Suboxone, Induction of 24-42 hours effects: Bunavail: Day
Zubsolv, Bunavail) treatment for • Naloxone: 2-12 hours Headache, 1: induction
Neurotransmitter(s) (CYP 450 enzyme) (link to NT or affected Considerations
Affected brain circuit) Specific lifespan
Target Symptoms considerations (age,
pregnancy,
breastfeeding)
Buprenorphine • Indications: • Metabolized by • Notable side • Initial dosing:
(Subutex) Induction of CYP450 3A4. effects: Day 1: 8 mg
treatment for • Elimination half-life of Headache, Day 2: 12-16
opioid dependence sublingual constipation, mg Days 3-7:
(Bunavail only), buprenorphine is 24-42 nausea, oral Increase in
maintenance hours. hypoesthesia, increments of 4
treatment of • Elimination half-life glossodynia, mg, maximum
opioid dependence naloxone is 2-12 hours. orthostatic 32 mg.
(sublingual), • Implant: Tmax is 12 hypotension, • Consideration
maintenance hours; time to steady implant specific: s: Use with
state is 4 weeks.
treatment of insertion site caution in the
opioid dependence pain, pruritus, elderly and
in patients who erythema. those with
have achieved and • Life- cardiac
sustained threatening side impairment. It
prolonged clinical effects: may be
stability on low- Respiratory preferable to
to-moderate doses depression, methadone in
(no more than hepatoxicity. pregnant
8mg) of a • How drug women.
transmucosal causes side Neonatal
buprenorphine- effects: Binding withdrawal
containing product at mu opioid may occur. The
(implant), receptors. drug is found in
moderate to serve breast milk and
opioid use is
disorder in recommended
NR 546 week 6 medication table
, patients who have for DC drug or
initiated treatment bottle feed.
with a Safety and
transmucosal efficacy have
buprenorphine- not been
containing established for
product, followed children and
by dose adolescents.
adjustment for a
minimum of 7
days (injection).
• Neurotransmitter
s affected: Mu
opioid receptor
partial agonist.
Binds with a
strong affinity to
the mu opioid
receptor,
preventing
exogenous opioids
from binding there
and thus
preventing the
pleasurable effects
of opioid
consumption.
• Target
symptoms: opioid
dependence.
Buprenorphine/ • Indications: • Half-life: Suboxone: • Notable side • Initial dosing:
Naloxone (Suboxone, Induction of 24-42 hours effects: Bunavail: Day
Zubsolv, Bunavail) treatment for • Naloxone: 2-12 hours Headache, 1: induction
